• Elite Pharmaceuticals Inc., of Northvale, N.J., entered a bridge loan agreement with Jerry Treppel, its chairman and CEO, who will provide the firm a line of credit not to exceed $500,000. Proceeds will be used to support Elite's acceleration of product development activities. The company develops oral sustained- and controlled-release products.

• Pharming Group NV, of Leiden, the Netherlands, said it redeemed the final tranche of its €8.4 million (US$10.6 million) convertible bond. A total of 45.6 million shares were issued to the bondholders and the company's total number of outstanding shares increased to 670.7 million. Pharming is developing Ruconest, a recombinant human C1 inhibitor for hereditary angioedema.

• Trovagene Inc., of San Diego, said underwriters exercised their full overallotment in its recent public offering to purchase an additional 172,500 units priced at $8 apiece. Added to the public offering of 1.15 million units, the total gross proceeds from the offering reached $10.6 million. Aegis Capital Corp. acted as sole book-running manager, while Summer Street Research and Brean Murray, Carret & Co. served as co-managers. Trovagene develops technology to detect transrenal DNA and RNA originating from normal and disease cell death that cross the kidney barrier and can be detected in urine.